Recruiting
Phase 1

DNase I

Sponsor:

McMaster University

Code:

NCT05453695

Conditions

Sepsis

Critical Illness

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Intravenous DNase I

Study Details

Brief summary:

Phase I dose-escalation safety and feasibility of IV DNase I in ICU septic patients.

Conditions

Sepsis

Critical Illness

Study ID

NCT05453695

Start date

Jan 17, 2023

Status verified date

Apr, 2025

Completion date

Sep 30, 2026

Anticipated

Primary completion date

May 28, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Age of ≥18 years
2. Admitted to the ICU in the last 48 hours
3. Suspected or proven infection as the admitting diagnosis
4. A sequential (sepsis) organ function assessment (SOFA) score of ≥2 above baseline
5. Expected to remain in the ICU for ≥ 72 hours

Exclusion Criteria:

1. No consent/inability to obtain consent from a substitute decision-maker
2. Have other forms of clinically apparent shock, including cardiogenic, obstructive (massive pulmonary embolism, cardiac tamponade, tension pneumothorax), hemorrhagic, neurogenic, or anaphylactic shock
3. Have a significant risk of bleeding as evidenced by one of the following:

  • Surgery requiring general or spinal anesthesia within 24 hours before enrolment
  • The potential need for surgery in the next 24 hours
  • Evidence of active bleeding
  • A history of severe head trauma requiring hospitalization
  • Intracranial surgery, or stroke within three months before the study
  • Any history of intracerebral arteriovenous malformation, cerebral aneurysm, or mass lesions of the central nervous system
  • A history of congenital bleeding diatheses
  • Gastrointestinal bleeding within five weeks before the study unless corrective surgery had been performed
  • Trauma is considered to increase the risk of bleeding
  • Presence of an epidural catheter
  • Need for therapeutic anticoagulation
4. Receiving DNase I by inhalation
5. Terminal illness with a life expectancy of fewer than three months
6. Pregnant and/or breastfeeding

Study Design

Enrollment

36 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Intravenous DNase I

We will enroll up to 36 Participants; each is receiving repeated unit doses of DNase I, BID, delivered by IV infusion over 3 or 7 consecutive days (12 +/- 1 hour apart) according to the following dose-escalation schedule with up to 6 Participants per dose panel.

  • Panel 1: 25 µg/kg, BID for 3 days (cumulative dose: 150 µg/kg)
  • Panel 2: 25 µg/kg, BID for 7 days (cumulative dose: 350 µg/kg)
  • Panel 3: 125 µg/kg, BID for 3 days (cumulative dose: 750 µg/kg)
  • Panel 4: 125 µg/kg, BID for 7 days (cumulative dose: 1750 µg/kg)

no intervention: Control

We will also enroll 12 septic Participants who do not receive intravenous DNase I (as Comparator Group). These patients will be recruited contemporaneously based on the same inclusion and exclusion criteria.

Interventions

Intravenous DNase I

Dose-escalating intravenous infusion of DNase I

Primary outcome measure

  • Number of patients recruited per month from the start of the study [ Time Frame: up to 24 months ]
  • Number of patients who completed the protocol [ Time Frame: up to 7 days ]

Central Contacts and Locations

Central contacts

Locations

Hamilton Health Sciences

Recruiting

Hamilton, Ontario, Canada, L8L 0A4

More Information

Sponsor

McMaster University

Last update posted

Mar 3, 2026

Last verified

Apr, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by McMaster University on 2026-03-03.